Group members NAMES KHUSHALI THAKORE KHUSHALI JAIN KHYATI PATEL KONICA JAIN KRUNAL MEHTA

Group No.1

ROLL NO. 10061 10062 10063 10064 10065

Introduction

Creating Value, Continuously

83 1995 1983 Began with 5 products First API Plant Panoli 2004 10 2007

1993

USD 350mn FCCB raised 1997

Demerger of innovative R&D to SPARC

First Research Centre SPARC, Baroda

1994 $7.5Mn invested in Caraco IPO - Rs. 550 Mn raised

PART OF

2010 The performance continues

Sun Pharma Today

5 Key operating subsidiaries 8,000+ Employees

Invested Rs. 17 billion in Research

19 Manufacturing facilities in 4 Continents

More than 50% of sales from international markets

Manufacturing Locations
Plants across four continents enables us to compete with a tight handle on cost and time to market across the geographies
India Americas
Detroit Bryan Cranbury Tennessee Jammu Sikkim Plant Halol Iztapalapa (Mexico)

Ankleshwar

Karkhadi Ahmednagar

Bangladesh Plant

Goinia (Brazil)

Panoli Silvassa Dadra

Europe

Maduranthakam

Tiszavasvari (Hungary)

API and Formulations

API

Formulations

Vision, mission & values

Vision : To brand register in major markets of the world. Mission : To lead globally in pharma sector. To strengthen the market share & focus on customers needs.

REVENUE COMPOSITION
2009-10 Annual sales : Rs 40,761 million
5 Year CAGR 26%

India Branded Generics

5 Year CAGR 22%
45%

APIs
5 Year CAGR 19%
13% 12%

30%

US Generics
International Branded Generics (ex-US)
5 Year CAGR 43%

5 Year CAGR 33%

PHARMACEUTICAL MARKET
GLOBAL SCENARIO

INDIAN PHARMA MARKET

India Branded Generics : Strong Base

Therapywise Break-up Market Share 3.7% Leadership in chronic segment; Top 3 in over 50% of more than 500 brands
Opthalmology- 4% Antiasthamatic & Antiallergic - 5% Musculo-Skeletal & Pain - 5% Gynecology & Urology - 7% Others 8% Neuro-Psychiatry 27%

Gastroenterology 14% Diabetology 11%

Cardiology 19%

Mergers & acquisitions

Year 2009 2008 Acquisition Caraco acquired some products of Forests Inwood business Acquired Chattem Chemicals, Inc. Country US Tennessee, US Rationale Increased generic product offerings Import registration with DEA, API Plant approved by DEA in Tennessee, US

2005
2005 2005 2004 2004 2000 1999 1998 1997 1997 1996 1996

Assets of Able labs

Formulation plant in Bryan Acquired ICN Hungary Womens Health Brands Merged Phlox Pharma Merged Pradeep Drug Company Ltd (PDCL) Merged Milmet Labs Brands from Natco Acquired Caraco Merged Tamilnadu Dadha Pharmaceuticals Ltd (TDPL) Acquired MJ Pharma Acquired Gujarat Lyka

New Jersey, US
Ohio, US Hungary US Baroda, India Chennai, India India India Detroit, US Chennai, India Halol, India Ankleshwar, India Ahmednagar, India

Dosage form plant (NJ, US) and IP

Dosage form plant (Ohio, US) API and dosage form plant (Hungary) Brands in womens health (US) API Plant API Plant Ophthalmology brands Respiratory brands Dosage form Plant Gynecology and oncology brands; API and dosage form plant Dosage form plant (now USFDA approved) API plant

1996

Bulk Drug plant from Knoll Pharma

API plant (now USFDA approved)

Shareholding pattern
as on 31st july10
Individuals and others 6% Bodies Corporate 5% Financial Inst / Banks 3% Mutual Funds 3%

FIIs / Foreign Banks 20%

Promoter and Promoter group 63%

FINANCE

SALES & PAT

70000 60000

50000

40000

Figures in million

PAT
30000

Sales
20000

10000

2005-2006

2006-2007

2007-2008

2008-2009

2009-2010

Year

Profit ratio & ROI

60% 50%

40%

Value in Percentage

30%
NPAT ROI

20%

10%

0%

2005-2006 2006-2007 2007-2008 2008-2009 2009-2010 Year

INVENTORY TURNOVER
8 7 6 5

No. of times

4 3 2 1 0 2005-2006 2006-2007 2007-2008 2008-2009 2009-2010

Inventory Turnover

Year

DEBT-EQUITY RATIO
1.4

1.2

0.8

Value

0.6

Debt Equity

0.4

0.2

2005-2006

2006-2007

2007-2008 Year

2008-2009

2009-2010

CURRENT RATIO
12

10 8
6

Value

4 2 0 2005-2006 2006-2007 2007-2008 2008-2009 2009-2010

Current Ratio

Year

EARNINGS PER SHARE

100 90 80 70 60 50

Rs.

40 30 20 10 0

2005-2006

2006-2007

2007-2008

2008-2009

2009-2010

Year

Reasons for growth

INDIAN HEALTH CARE OPPORTUNITY CONCENTRATION OF CHRONIC INTERNATIONAL MARKET MERGERS AND ACQUISITIONS

Research & Development

Generic R&D spend around 8% of net sales
Strong research teams in generics, finished dosage development, biological support, chemistry 2 R&D centers with about 600 scientists
Mumbai

Immediate term ANDA, DMF, Products for India

Balancing the risk

Medium term Drug delivery systems

Baroda

Corporate Governance
Our philosophy on corporate governance envisages working towards high levels of transparency, accountability and consistent value

systems across all facets of operations

Audit Committee

Accountability Responsibilty Fareness Consistent Value

Committee chaired by Keki Mistry comprises Hasmukh Shah and S. Mohanchand Dadha

Corporate social responsibilty

Environmental issues Handle waste Minimize environment contamination Reducing pollution

THANK YOU